ImmunoGen, Inc. IMGN
Set alert
31.24 +31.24 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 8.73B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 86.75
- Beta
- 1.17
- Short ratio
- 3.78
- Inst. own
- 86.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 6, 2024
- 50-d avg
- 29.71
- 200-d avg
- 19.72
- 1y target
- 25.50
Analyst view
Consensus: buy
Buy
Price target (mean) 25.50 -18.4% downside
Now 31.24
- Target (low)
- 16.00
- Target (mean)
- 25.50
- Target (high)
- 31.00
Ratings (0m) 9 5 buy · 3 hold · 1 sell
- Strong buy4
- Buy1
- Hold3
- Sell1
- Strong sell0
Recommendation trend
- This month 9
- 1 month ago 13
- 2 months ago 14
- 3 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.13 | 0.09 – 0.21 | -0.23 | +156.5% | 131.56M | +219.6% | 4 |
| Next quarter | -0.03 | -0.16 – 0.10 | -0.16 | +81.2% | 117.95M | +136.5% | 2 |
| Current year | 0.08 | 0.05 – 0.14 | -0.88 | +109.1% | 377.85M | +247.3% | 4 |
| Next year | 0.36 | 0.18 – 0.54 | 0.08 | +350.0% | 546.37M | +44.6% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | Oppenheimer | Initiated | — | Perform |
| Sep 12, 2023 | JP Morgan | Upgrade | Neutral | Overweight |
| Aug 28, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 1, 2023 | Barclays | Maintained | Overweight | Overweight |
| Jul 31, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 31, 2023 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 31, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 12, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 11, 2023 | Barclays | Maintained | — | Overweight |
| Jun 11, 2023 | Canaccord Genuity | Reiterated | Buy | Buy |
| Jun 5, 2023 | Truist Securities | Maintained | Buy | Buy |
| Jun 4, 2023 | Canaccord Genuity | Maintained | Buy | Buy |
| May 2, 2023 | Piper Sandler | Upgrade | Neutral | Overweight |
| Apr 30, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 1, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 22, 2023 | JP Morgan | Maintained | — | Neutral |
| Dec 29, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 20, 2022 | Truist Securities | Initiated | — | Buy |
| Nov 15, 2022 | Canaccord Genuity | Maintained | — | Buy |
| Nov 15, 2022 | BMO Capital | Maintained | — | Outperform |
| Nov 15, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 14, 2022 | Barclays | Maintained | — | Overweight |
| Sep 8, 2022 | Barclays | Initiated | — | Overweight |
| May 5, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Mar 20, 2022 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Feb 21, 2022 | SVB Leerink | Maintained | — | Market Perform |
| Feb 10, 2022 | BMO Capital | Initiated | — | Outperform |
| Nov 30, 2021 | Jefferies | Upgrade | Hold | Buy |
| Oct 28, 2021 | SVB Leerink | Maintained | — | Market Perform |
| Nov 5, 2020 | SVB Leerink | Maintained | — | Market Perform |